Related Experiment Video
Updated: Jun 24, 2025
09:01
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
14.0K
Acute lymphoblastic leukaemia.
Luca Pagliaro1,2,3, Sai-Juan Chen4, Daniel Herranz5
1Department of Medicine and Surgery, University of Parma, Parma, Italy.
Nature Reviews. Disease Primers
|June 13, 2024
Summary
Recent advances in acute lymphoblastic leukaemia (ALL) research have improved diagnosis and treatment. Innovations in omics medicine, targeted therapies, and CAR T-cell therapy offer new hope for patients with this blood cancer.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Acute lymphoblastic leukaemia (ALL) is a blood cancer marked by uncontrolled growth of immature lymphoid cells.
- Significant progress in understanding ALL biology has led to better diagnosis, treatment, and monitoring over decades.
Purpose of the Study:
- To review recent advancements in acute lymphoblastic leukaemia (ALL) research.
- To highlight innovations in diagnostics, targeted therapies, and supportive care for ALL patients.
Main Methods:
- Review of omics medicine and genomic profiling techniques.
- Analysis of targeted agents (tyrosine kinase inhibitors, immunotherapies) and CAR T-cell therapy.
- Evaluation of measurable residual disease monitoring and ex vivo drug response profiling.
Main Results:
- Genomic profiling has identified key genetic alterations driving ALL, informing new therapeutic strategies.
- Targeted agents and CAR T-cell therapy show significant efficacy in specific patient subgroups.
- Advanced monitoring techniques enable earlier relapse detection and personalized treatment adjustments.
Conclusions:
- Ongoing research and technological innovations are transforming ALL management.
- Personalized medicine approaches, including targeted therapies and advanced monitoring, are improving patient outcomes and quality of life.
More Related Videos
Related Concept Videos
01:27Disorders of Leukocytes
937
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
937
01:22Bone Marrow Sampling and Transplants
324
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
324
01:23Cells of the Adaptive Immune Response
979
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
979